Hormonal
Semaglutide 2.4 mg weekly produces substantial and durable weight loss (10-15%) in adults with overweight or obesity through central appetite suppression, delayed gastric emptying, and improved glucose homeostasis.
If you have obesity, semaglutide 2.4 mg taken once weekly is a highly effective treatment for significant weight loss (10-15%). It works by reducing appetite and slowing digestion. Start with a low dose to minimize stomach upset, which usually improves over time. It is a long-term commitment, not a quick fix.
Semaglutide promotes weight loss through central and peripheral mechanisms that reduce appetite, enhance satiety, delay gastric emptying, and improve glucose homeostasis... Clinical evidence shows notable reductions in body weight... ~10–15% weight loss
Why this rating
Based on a review of major clinical trials (STEP, SUSTAIN) and real-world analyses, though it is a review article rather than primary data.
Source
Semaglutide as a Cornerstone Therapy in Obesity: Clinical and Pharmacological Insights
Sagarika Basavaraj et al. · Journal of Pharmaceutical Research · 2026
DOI 10.18579/jopcr/v25.i1.10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →